Journal of Affective Disorders Dose Effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis

Psychedelics and Psychedelic-Assisted Psychotherapy

(2020) Collin M. Reiff et al.   AMERICAN JOURNAL OF PSYCHIATRY

Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression

(2020) Lea J Mertens et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer

(2020) Gabrielle I Agin-Liebes et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Denver votes to decriminalise psilocybin mushrooms

(2019) Paul Webster   LANCET

Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial

(2018) Somaye Arabzadeh et al.   JOURNAL OF AFFECTIVE DISORDERS

Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study

(2018) Yoav Domany et al.   BRITISH JOURNAL OF PSYCHIATRY

Serotonin and brain function: a tale of two receptors

(2017) RL Carhart-Harris et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future

(2017) Robin L Carhart-Harris et al.   NEUROPSYCHOPHARMACOLOGY

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

(2017) R. L. Carhart-Harris et al.   PSYCHOPHARMACOLOGY

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

(2016) Roland R Griffiths et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

(2016) Stephen Ross et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis

(2016) Toshi A Furukawa et al.   BMJ Open

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

(2015) Frederick S Barrett et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Research on Acute Toxicity and the Behavioral Effects of Methanolic Extract from Psilocybin Mushrooms and Psilocin in Mice

(2015) Olga Zhuk et al.   Toxins

Systematic meta-analyses and field synopsis of genetic association studies of violence and aggression

(2013) E Vassos et al.   MOLECULAR PSYCHIATRY

Power failure: why small sample size undermines the reliability of neuroscience

(2013) Katherine S. Button et al.   NATURE REVIEWS NEUROSCIENCE

A fatal case of ‘magic mushroom’ ingestion in a heart transplant recipient

(2012) T. H. Lim et al.   INTERNAL MEDICINE JOURNAL

Development of Lifetime Comorbidity in the World Health Organization World Mental Health Surveys

(2011) Ronald C. Kessler et al.   ARCHIVES OF GENERAL PSYCHIATRY

Definition and classification of cancer cachexia: an international consensus

(2011) Kenneth Fearon et al.   LANCET ONCOLOGY

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

(2011) Roland R. Griffiths et al.   PSYCHOPHARMACOLOGY

Harm potential of magic mushroom use: A review

(2011) Jan van Amsterdam et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

(2010) Charles S. Grob et al.   ARCHIVES OF GENERAL PSYCHIATRY

Cachexia: A new definition

(2008) William J. Evans et al.   CLINICAL NUTRITION

Human hallucinogen research: guidelines for safety

(2008) MW Johnson et al.   JOURNAL OF PSYCHOPHARMACOLOGY